New scan could spot hidden aggressive prostate cancer in men who think They're safe

NCT ID NCT05852041

First seen Jul 02, 2026 ยท Last updated Jul 02, 2026

Summary

This study tests whether a special PET-MRI scan using a radioactive tracer called rhPSMA-7.3 can find higher-risk prostate cancer that standard tests might miss. Men with low-risk or favorable intermediate-risk prostate cancer who are candidates for active surveillance will receive the scan before a prostate biopsy. The goal is to see if the scan better identifies those who actually need treatment rather than just monitoring.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Flotufolastat F-18 Gallium (rhPSMA-7.3)
What this could lead to
If successful, this imaging method could help identify men who need immediate treatment rather than active surveillance, potentially catching aggressive prostate cancer earlier.
What could go wrong
This is a small early-phase pilot study, so results may not apply broadly. The radioactive tracer may not reliably distinguish aggressive from slow-growing cancers, and there are risks from radiation exposure and biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.